FI72139C - Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. - Google Patents
Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. Download PDFInfo
- Publication number
- FI72139C FI72139C FI820233A FI820233A FI72139C FI 72139 C FI72139 C FI 72139C FI 820233 A FI820233 A FI 820233A FI 820233 A FI820233 A FI 820233A FI 72139 C FI72139 C FI 72139C
- Authority
- FI
- Finland
- Prior art keywords
- globulin
- lymfosyt
- foerfarande foer
- foer framstaellning
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/85—Reproductive organs or embryos
- Y10S530/851—Placenta; amniotic fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
1 72139
Anti-T-lymfosyytti-globuliinin valmistus - Förfarande för framställning av anti-T-lymfosyt-globulin
Keksinnön kohteena on anti-T-lymfosyytti-globuliinin valmistus immunisoitujen eläinten seerumista.
Suuritehoisia immuunisuppressiiveja käytetään elinsiirroissa siirrosteeseen kohdistuvan hylkimisen pienentämiseen ja luuydinsiirroissa luovuttajan ja isännän välisten sairauksien hoitoon. Niiden valmistus on tapahtunut tähän mennessä siten, että lymfasoluja ruiskutetaan eläimen, esimerkiksi hevosen tai kaniinin kehoon ja anti-lymfosyytti-globuliini otetaan talteen immunisoidun eläimen seerumista. Tämän valmistusmenetelmän haittana on, että menetelmässä käytetään lymfasoluja, joiden hankkiminen aiheuttaa eettisiä ongelmia ja joita on käytettävissä vain rajoitettu määrä.
Keksinnön tavoitteena on käyttää immunosuppressiivin valmistukseen in vitro kasvatettuja soluja.
Hakija on yllättäen havainnut, että käytettäessä immunisointiin JM-solulinjän soluja on mahdollista valmistaa immuno-suppressiivi, jolla on erinomainen vaikutus. JM-solulinjän valmistus ja ominaisuudet on kuvattu U. Schneider'in, H.U. Schwenk'in ja G. Bornkamm'in julkaisussa, Int. J. Cancer 19, 621-626 (1977). JM-solulinja on tallennettu numerolla I 147 Pasteuer-instituutin kokoelmaan, Institut Pasteuer Collection Nationale de Culture des Microorganismes (C.N.C.M.). Soluja voidaan lisätä mielivaltaisesti in vitro niiden menettämättä ominaisuuksiaan.
Anti-T-lymfosyyttiglobuliini otetaan edullisesti talteen immunisoitujen kaniinien seerumista.
2 72139
Seuraavassa on kuvattu suoritusesimerkki anti-tymosyyttiglobu- liinin valmistamisesta käyttämällä T-lymfoblasti-solulinjaa-JM.
Esimerkki muodostuu seuraavista vaiheista: 1. Sentrifugoidaan T-lymfoblasti-solut.
2. Säädetään solususpensio fysiologisella solualustalla (CL 15), solukonsentraatioon 30 x 10^ solua/ml.
3. Immunisoidaan kaniinit applikoimalla laskimonsisäisesti 3 ml solususpensiota korvalaskimoon.
4. Valutetaan veri eläimistä 4-viikkoisen immunisointiajän jälkeen.
5. Seerumi otetaan talteen sentrifugoimalla veri.
6. Kaniinien veri yhdistetään vasta-ainetiitterin määrittämisen ja steriil isyyden tutkimisen jälkeen.
7. Absorboidaan seerumi erilaisilla ihmissoluilla.
8. Puhdistetaan antiseerumi globuliinifraktiointia varten saostamalla ammoniumsulfaatilla ja sen jälkeen käsittelemällä pylväskromatograafisesti.
9. Immunoglobuliinijae säädetään määrättyyn valkaisuaine-pitoisuuteen (20 mg/ml).
10. Tämän jälkeen ultrasentrifugoidaan anti-tymosyytti-globuliini ja suodatetaan steriiliksi.
11. Immunoglobuliini täytetään ampulleihin ja suoritetaan loppukontrolli (testataan laatu, steriilisyys ja pyrogeenipitoisuus).
Il
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813105150 DE3105150A1 (de) | 1981-02-12 | 1981-02-12 | Herstellung von anti-t-lymphozyten-globulin. |
| DE3105150 | 1981-02-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI820233L FI820233L (fi) | 1982-08-13 |
| FI72139B FI72139B (fi) | 1986-12-31 |
| FI72139C true FI72139C (fi) | 1987-04-13 |
Family
ID=6124731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI820233A FI72139C (fi) | 1981-02-12 | 1982-01-26 | Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4541953A (fi) |
| AT (1) | AT377698B (fi) |
| AU (1) | AU550257B2 (fi) |
| BE (1) | BE891944A (fi) |
| CA (1) | CA1184491A (fi) |
| CH (1) | CH652410A5 (fi) |
| DE (1) | DE3105150A1 (fi) |
| DK (1) | DK56882A (fi) |
| ES (1) | ES8401982A1 (fi) |
| FI (1) | FI72139C (fi) |
| FR (1) | FR2499413B1 (fi) |
| GB (1) | GB2093037B (fi) |
| HU (1) | HU189998B (fi) |
| IT (1) | IT1195296B (fi) |
| LU (1) | LU83932A1 (fi) |
| NL (1) | NL8200458A (fi) |
| NO (1) | NO157422C (fi) |
| SE (1) | SE460826B (fi) |
| ZA (1) | ZA82905B (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE60233T1 (de) * | 1983-09-15 | 1991-02-15 | Univ Leland Stanford Junior | Allotransplantat mit verminderter immunogenitaet und verfahren und reagenz fuer seine herstellung. |
| US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US5011684A (en) * | 1985-09-05 | 1991-04-30 | Beth Israel Hospital Association | Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance |
| US5785966A (en) * | 1994-06-15 | 1998-07-28 | Coles; John G. | Inhibition of human xenogenic or allogenic antibodies to reduce xenograft or allograft rejection in human recipients |
| FR2878852B1 (fr) * | 2000-09-28 | 2007-02-23 | Imtix Sangstat | Procede de production d'immunoglobulines anti-thymocytes humains |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363799A (en) * | 1979-03-20 | 1982-12-14 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human T cells, and methods for preparing same |
| US4361549A (en) * | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4364935A (en) * | 1979-12-04 | 1982-12-21 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human prothymocyte antigen and methods of preparing same |
| US4364933A (en) * | 1979-12-04 | 1982-12-21 | Ortho Pharmaceutical Corporation | Monoclonal antibody to a human thymocyte antigen and methods of preparing same |
| US4361550A (en) * | 1979-12-04 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same |
-
1981
- 1981-02-12 DE DE19813105150 patent/DE3105150A1/de active Granted
- 1981-11-23 GB GB8135192A patent/GB2093037B/en not_active Expired
- 1981-11-24 IT IT25247/81A patent/IT1195296B/it active
- 1981-12-11 FR FR8123180A patent/FR2499413B1/fr not_active Expired
-
1982
- 1982-01-05 NO NO820014A patent/NO157422C/no unknown
- 1982-01-14 AT AT0011482A patent/AT377698B/de not_active IP Right Cessation
- 1982-01-26 FI FI820233A patent/FI72139C/fi not_active IP Right Cessation
- 1982-01-29 BE BE0/207174A patent/BE891944A/fr not_active IP Right Cessation
- 1982-02-04 SE SE8200639A patent/SE460826B/sv not_active IP Right Cessation
- 1982-02-05 NL NL8200458A patent/NL8200458A/nl not_active Application Discontinuation
- 1982-02-08 CA CA000395714A patent/CA1184491A/en not_active Expired
- 1982-02-10 LU LU83932A patent/LU83932A1/de unknown
- 1982-02-10 DK DK56882A patent/DK56882A/da not_active Application Discontinuation
- 1982-02-11 ES ES509504A patent/ES8401982A1/es not_active Expired
- 1982-02-11 AU AU80373/82A patent/AU550257B2/en not_active Ceased
- 1982-02-11 HU HU82426A patent/HU189998B/hu not_active IP Right Cessation
- 1982-02-12 ZA ZA82905A patent/ZA82905B/xx unknown
- 1982-02-12 CH CH905/82A patent/CH652410A5/de not_active IP Right Cessation
-
1984
- 1984-02-21 US US06/582,030 patent/US4541953A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| LU83932A1 (de) | 1982-07-07 |
| ATA11482A (de) | 1984-09-15 |
| US4541953A (en) | 1985-09-17 |
| DK56882A (da) | 1982-08-13 |
| ES509504A0 (es) | 1984-01-16 |
| SE460826B (sv) | 1989-11-27 |
| NO157422B (no) | 1987-12-07 |
| FR2499413B1 (fr) | 1985-08-30 |
| HU189998B (en) | 1986-08-28 |
| IT8125247A0 (it) | 1981-11-24 |
| SE8200639L (sv) | 1982-08-13 |
| NL8200458A (nl) | 1982-09-01 |
| GB2093037B (en) | 1984-07-18 |
| ZA82905B (en) | 1982-12-29 |
| AU8037382A (en) | 1982-08-19 |
| CA1184491A (en) | 1985-03-26 |
| FR2499413A1 (fr) | 1982-08-13 |
| AU550257B2 (en) | 1986-03-13 |
| IT1195296B (it) | 1988-10-12 |
| CH652410A5 (de) | 1985-11-15 |
| DE3105150A1 (de) | 1982-08-19 |
| ES8401982A1 (es) | 1984-01-16 |
| NO820014L (no) | 1982-08-13 |
| DE3105150C2 (fi) | 1989-02-23 |
| FI820233L (fi) | 1982-08-13 |
| BE891944A (fr) | 1982-05-17 |
| GB2093037A (en) | 1982-08-25 |
| NO157422C (no) | 1988-03-16 |
| FI72139B (fi) | 1986-12-31 |
| AT377698B (de) | 1985-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4309418A (en) | Anti-tumor agent from human serum and process | |
| CA1261258A (en) | Angiogenic factor and method for producing angiogenesis | |
| Van Meter et al. | Ontogeny of circulating immunoglobulins in normal, bursectomized and irradiated chickens | |
| Ellis et al. | Differentiation antigens on bovine mononuclear phagocytes identified by monoclonal antibodies | |
| US5529903A (en) | Extraction and cultivation of transformed cells and production of antibodies directed against them | |
| Gajl-Peczalska et al. | LOCALIZATION OF IMMUNOLOGICAL COMPLEXES FIXING ß1C (C3) IN GERMINAL CENTERS OF LYMPH NODES | |
| Moorhead et al. | IMMUNOLOGIC REACTIONS TO HAPTENS ON AUTOLOGOUS CARRIERS: I. Participation of Both Thymus-Derived and Bone Marrow-Derived Cells in the Secondary In Vitro Response | |
| Tizard | Macrophage cytophilic antibody in mice | |
| FI72139C (fi) | Foerfarande foer framstaellning av anti-t-lymfosyt-globulin. | |
| US5262334A (en) | Method for immunoselection of cells using avidin and biotin | |
| US4009257A (en) | Preparation of immunosuppressive materials | |
| Goldstein et al. | mAbs to human lymphocyte surface antigens | |
| Johnson et al. | Antibody-Mediated Suppression of Tumor Growth: I. Suppression by Murine IgG1 Isolated from Alloantiserum | |
| Aber et al. | Liver function after myocardial infarction | |
| Kashiwagi et al. | Antibody localization in horse, rabbit, and goat antilymphocyte sera | |
| Nishihara et al. | Masugi nephritis produced by the antiserum to heterologous glomerular basement membrane: I. Results in mice | |
| CA1188243A (en) | Chemorecruitins of leukocytes and inflamed tissues and process for their preparation | |
| Malchow et al. | Solubilization and partial purification of lymphocyte specific antigens in the chicken | |
| EP0419462A1 (en) | Improved immunotoxin therapies utilizing purified ricin a-chain species | |
| AT396936B (de) | Hybridoma zell-linien und verfahren zu ihrer herstellung sowie die verwendung der genannten zell-linien zur herstellung von monoklonalen antikörpern | |
| DE3919294C2 (de) | Verwendung eines monoklonalen Antikörpers zur Behandlung einer Autoimmunerkrankung | |
| SU811530A1 (ru) | Способ получени вещества,обладающего противоопухолевой активностью | |
| Garcia-Rinaldi et al. | Specific in vitro binding of radiolabeled antibodies to cell surface antigens: Interaction of antihuman thymocyte globulin with human target cells | |
| RU2272810C2 (ru) | Средство для активации стволовых клеток | |
| RU2283666C2 (ru) | Средство для активации восстановления структуры и функции поврежденных тканей и органов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: DR. EDUARD FRESENIUS |